given Ig sulphadimidine orally, and their urine was collected for 1 hour between 5 and 6 hours after ingestion of the drug. Urine samples were analysed for free and acetylated sulphadimidine by the method described by Schroder. Results were expressed as a percentage of the acetylated drug in the urine. Slow acetylators were defined as having less than 70% acetylated sulphadimidine in the urine.
A number of primary amine drugs such as dapsone, isoniazid, hydrallazine, procainamide, and many of the sulphonamides are acetylated by the N-acetyltransferase enzyme at rates which are bimodally distributed in man (Evans et al., 1960; Evans and White, 1964; Gelbert et al., 1971; Zacest and Koch-Weser, 1972; Karlsson et al., 1975) . Several of these drugs have been implicated in the development of systemic lupus erythematosus (SLE) (Alarcon-Segovia, 1976 ). This has been reported more frequently in slow acetylators of the suspected drug (Lunde et al., 1977) A total of 72 subjects were tested: 22 with spontaneous SLE as defined by the American Rheumatism Association criteria (Cohen et al., 1971) , 25 with either classical or definite rheumatoid arthritis (Ropes et al., 1959) , and 25 normal controls. All were attending hospital either as outpatients or as staff and were on normal diets. At the time of the study no patient was taking a drug which was metabolised by acetylation. All patients had normal renal function as shown by normal blood urea and serum creatinine concentrations at the time of the test. The mean ages, sex distribution, and blood urea concentrations in these subjects are shown in Table 1 .
Results
The distribution of acetylator capacity in the 3 groups of subjects studied is shown in Fig. 1 . Of the acetylation capacity using isoniazid half-times in plasma in a group of 15 patients with SLE who were not taking concurrent drug therapy. Only 2 of these patients were rapid acetylators. However, 7 of them had chronic renal failure with glomerular filtration rates between 17 and 41 ml/min-a factor which could introduce difficulties in measuring acetylator capacity. A similar problem exists in the data presented by Reidenberg and Martin (1974) . Moreover, Molin et al. (1977) showed that, although the distribution of slow and fast acetylators of sulphapyridine was 50: 50 in Sweden when studying normal individuals, a distinct bias towards slow acetylators was apparent when patients admitted to hospital for cardiac or renal diseases were studied. Thus it is not clear from these observations whether Normals the reported trend towards fewer than normal fast acetylators in patients with spontaneous SLE is a tylated reflection of the disease itself or of extraneous SLE, factors associated with attendance at hospital. The present study compares the acetylator capacity of outpatients with spontaneous SLE with that of 2 other groups, one of which had rheumatoid arthritis lators (27 /o) and one of which was normal. It fails to confirm that )id arthritics acetylator phenotype is a useful marker for the 36 %). These spontaneous form of SLE. 
